Ann: Cynata Expands trial in COVID-19 & Respiratory Failure, page-156

The goss is, Fuji has done nothing with your lead product, you know, the only product that has completed a small P1 trial in 2018, in GVHD. And here we are, 2021, nothing happening. It was meant to be the easy, proof of concept, the lead candidate. And when Ross was asked, he said something like, it none of our business, we have no idea what they are doing, that's for them. Another P2 could have been done, and could be on sale in Japan by now. Self-funding, burning cash, keeps control of your destiny.

Oh, and the takeover stalled because of "structural" problems. Would that have anything to do with the expiring of the contract you have?

Thanks for the question sector, keep em coming. Plenty of ugly to talk about.